Bionano Genomics, Inc. Stock: price and management transactions · United States · SEC (Form 4)

About Bionano Genomics, Inc.

Bionano Genomics, Inc. is a United States-based life sciences and genomics technology company listed on the NASDAQ market. Headquartered in San Diego, California, the company focuses on optical genome mapping (OGM), a genomic analysis approach designed to detect structural variation and other large-scale DNA changes that can be difficult to characterize with conventional sequencing workflows. Company materials indicate that Bionano was originally founded in 2003 as BioNanomatrix and later evolved into Bionano Genomics as it expanded its commercial footprint and product portfolio. ([ir.bionano.com](https://ir.bionano.com/static-files/0a1c1d2c-f90c-407b-b436-a0ba28e49e12?utm_source=openai)) The company’s core business is built around an integrated genomics platform that combines instruments, consumables, software, and laboratory services. Its flagship Saphyr system is used to generate high-resolution genome maps, while adjacent software tools support data interpretation in cytogenetics and molecular pathology. Bionano also offers lab services for customers that want access to OGM-generated data without deploying the platform in-house. This creates a relatively broad commercial model: Bionano is not just an instrument vendor, but a workflow provider spanning sample processing, analysis, and interpretation. ([ir.bionano.com](https://ir.bionano.com/static-files/43cc3af0-d812-4743-b2b0-dc12def33d44?utm_source=openai)) From a competitive standpoint, Bionano operates in a specialized but strategically important segment of genomics focused on research, clinical cytogenetics, and selected oncology and rare-disease applications. Its main differentiator is the ability of OGM to capture large structural variants and complex genomic rearrangements that are often missed or incompletely resolved by standard methods. In that sense, Bionano positions itself as either an alternative to or a complement to traditional genomic testing workflows. ([bionano.com](https://bionano.com/?utm_source=openai)) Recent developments point to a company in restructuring mode. In its 2024 update, Bionano said it had pursued significant cost reductions to improve its path toward profitability while continuing to advance OGM and software adoption. The company also reported growth in its installed OGM base at year-end 2024. More recent disclosures suggest a strategic focus on routine users of its OGM solutions and broader adoption in both the United States and international markets. For investors, Bionano remains a highly specialized NASDAQ-listed genomics name with a differentiated technology platform, but also one that continues to face the execution and financing pressures typical of small-cap biotech and life-science instrumentation companies. ([ir.bionano.com](https://ir.bionano.com/news-releases/news-release-details/bionano-reports-preliminary-fourth-quarter-and-full-year-2024/?utm_source=openai))